Praxis Precision Medicines

This study is testing whether a new drug called elsunersen can safely reduce seizures in young children with a rare and severe form of genetic epilepsy (SCN2A-DEE). It will involve about 50 children who started having seizures before 3 months old. Some children will receive the r…

This Phase 3 trial is testing whether a new drug called relutrigine can safely reduce seizure frequency in children and adults with a severe form of epilepsy called developmental and epileptic encephalopathy (DEE). About 160 participants will receive either the drug or a placebo …